Protsenko · PloS one 2020 · population health modeling study · n=?

Are long telomeres better than short? Relative contributions of genetically predicted telomere length to neoplastic and non-neoplastic disease risk and population health burden.

Cited 31 times in the scientific literature.

Level 3 - non-randomized controlled study

Population health modeling and risk projection using summary data from Mendelian randomization meta-analysis and registries (design analogy)

PubMed 33031470 · doi:10.1371/journal.pone.0240185 · record verified 2026-08-30

What was done

The authors modeled the population-level disease incidence and burden associated with genetically determined leukocyte telomere length (gTL). Disease odds ratios from a published Mendelian randomization (MR) meta-analysis were combined with incidence and Disability-Adjusted Life Years (DALY) data from the Institute for Health Metrics and Evaluation (IHME) and SEER cancer records for a European population. They calculated the excess incidence and DALYs per 100,000 persons per standard deviation (SD) change in gTL across 9 cancers associated with long gTL and 4 degenerative diseases associated with short gTL.

What was found

Long gTL was associated with an excess incidence of 94.04 cases per 100,000 persons per SD (95% CI: 45.49 to 168.84) across 9 cancers, while short gTL was associated with an excess incidence of 121.49 cases per 100,000 persons per SD (95% CI: 48.40 to 228.58) across 4 non-neoplastic diseases. In terms of overall population disease burden, long gTL contributed an excess 1,255.25 DALYs per 100,000 persons per SD (95% CI: 662.71 to 2,163.83) due to cancer, compared to an excess 1,007.75 DALYs per 100,000 persons per SD (95% CI: 411.63 to 1,847.34) from degenerative conditions.

Why it matters

This paper quantitatively supports the cancer-aging trade-off, showing that while long telomeres carry higher relative risks for specific cancers, the higher baseline population incidence of degenerative diseases balances the net disease burden of short telomeres.

Limits

The study is a mathematical projection based on aggregated summary-level data rather than individual longitudinal follow-up. The analysis is limited to a European population and only includes the 9 cancers and 4 non-neoplastic diseases established in prior MR studies. The total underlying sample size across registries and MR studies is not reported in the abstract.

Cited by